Skip to content

Interleukin-38 Levels in Individuals With Periodontitis

Evaluation of Interleukin-38 Levels in Individuals With Healthy and Periodontal Disease

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05568290
Enrollment
75
Registered
2022-10-05
Start date
2022-09-30
Completion date
2022-12-10
Last updated
2022-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gingivitis, Healthy, Periodontitis

Keywords

periodontal disease, IL-38

Brief summary

Interleukin (IL)-38 is the newest member of the IL-1 family. It can bind to receptors through various pathways and regulate the formation and function of inflammatory cytokines. Periodontitis is a chronic inflammatory disease that can start with localized inflammatory reactions created by the supporting tissues surrounding the teeth against microorganisms and then result in loss of teeth. The aim of this study is to compare the IL-38, IL-1β and IL-10 levels of healthy and periodontitis individuals.

Detailed description

Periodontitis is a destructive chronic inflammatory disease that can start with localized inflammatory reactions created by the supporting tissues surrounding the teeth against microorganisms and then result in loss of teeth. More than any other cytokine family, the interleukin (IL)-1 family (IL-1α, IL-1β, IL-18, IL-33, IL-36α, IL-36β, IL-36γ, IL-1Ra, IL-36Ra, IL-37, IL-38) includes key signaling molecules that trigger and perpetuate periodontal inflammation. Interleukine -1β ( IL-1β ) levels are associated with periodontal destruction in the pathogenesis of periodontal disease. Interleukine-10 (IL-10) has been reported to decrease periodontal disease progression rate. Gingival crevicular fluid shows the cellular response in the periodontium. The most important host-related ingredients are inflammatory markers, including cytokines, enzymes, and interleukins. Saliva analysis is used in the diagnosis of systemic conditions as well as in the diagnosis of oral pathologies. In recent studies, IL-38 expression has been reported to be abnormal (abnormal) in chronic inflammatory diseases, especially in rheumatoid diseases such as systemic lupus erythematosus, rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Therefore, this relationship of this inflammatory cytokine with chronic inflammatory diseases draws attention to the regulatory effect of IL-38 in these diseases. The aim of this study is to compare the IL-38, IL-1β and IL-10 levels of healthy and periodontitis individuals.

Interventions

OTHERSaliva

individuals' saliva samples will be collected and transferred to eppendorf tubes. Until biochemical analysis is carried out will be stored in -80ºC.

GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes.Until biochemical analysis is carried out will be stored in -80ºC.

Sponsors

Saglik Bilimleri Universitesi
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* systemically healthy individuals who does not have a disease under treatment, * individuals without regular systemic medication

Exclusion criteria

* smoking * receiving periodontal treatment in the last 6 months * pregnancy * lactation

Design outcomes

Primary

MeasureTime frameDescription
IL-38 levelsinitial examination, baselinesaliva and DOS levels
IL-1β levelsinitial examination, baselinesaliva and DOS levels
IL-10 levelsinitial examination, baselinesaliva and DOS levels

Secondary

MeasureTime frameDescription
Plaque Indexinitial examination, baselineSilness-Löe
Probing Depthinitial examination, baselinemillimeter
Bleeding on Probeinitial examination, baselineAinamo&Bay

Countries

Turkey (Türkiye)

Contacts

Primary ContactAyşe Toraman, Dr
draysetoraman@gmail.com05385025422

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026